Related Experiment Videos
Targeting survivin in cancer
1Prostate Cancer Discovery and Development Program, The Wistar Institute Cancer Center, Philadelphia, PA 19104, USA. daltieri@wistar.org
Cancer Letters
|March 14, 2012
Summary
Survivin, a protein found in human tumors, has multiple functions. Despite progress and clinical trials, few survivin antagonists are available, necessitating new drug development approaches.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Survivin is a protein with numerous functions implicated in various human tumors.
- Extensive research has elucidated survivin's roles in cellular networks and its presence in cancer.
- Over 4000 citations in Medline highlight significant global research interest in survivin.
Purpose of the Study:
- To review the progress in understanding survivin biology and its therapeutic implications.
- To highlight the transition of survivin research from basic science to clinical applications.
- To identify the challenges and opportunities in developing survivin-based cancer therapeutics.
Main Methods:
- Literature review of survivin research and clinical trial data.
- Analysis of survivin's known functions and cellular network integration.
- Evaluation of the current landscape of survivin antagonists in cancer therapy.
Main Results:
- Significant advancements have been made in understanding survivin's diverse biological functions.
- Survivin's role has been mapped in numerous human tumor types.
- Several survivin-based therapeutics have entered clinical trials, demonstrating therapeutic potential.
Conclusions:
- A deeper understanding of survivin biology has successfully translated into clinical investigations.
- The limited number of approved survivin antagonists underscores a need for innovative drug development strategies.
- Fully realizing survivin's potential as an oncology target requires a more flexible approach to therapeutic development.
Related Concept Videos
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...